NeuroVive Pharmaceutical AB Предполагаемая прибыль на акцию Q/Q
Что обозначает Предполагаемая прибыль на акцию Q/Q в NeuroVive Pharmaceutical AB?
Предполагаемая прибыль на акцию Q/Q NeuroVive Pharmaceutical AB является N/A
Какое определение для Предполагаемая прибыль на акцию Q/Q?
Предполагаемый ежеквартальный темп роста EPS, ежегодно представляет собой предполагаемое увеличение EPS компании в следующем квартале по сравнению с показателями прошлого соответствующего квартала.
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Что делает NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.